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Abstract
Background: Some clinical symptoms or cognitive functions have been related to the overall state
of monoamine activity in patients with schizophrenia, (e.g. inverse correlation of the dopamine
metabolite HVA with delusions or visual-masking performance). However, profiles (as presented
here) of the relations of the activity of dopamine, noradrenaline and serotonin to neuropsychologic
(dys)functions in major patient sub-groups with their very different symptomatic and cognitive
characteristics have not been reported.
Methods: Serum measures of dopamine, noradrenaline and serotonin turnover were examined
by regression analyses for the prediction of performance on 10 neuropsychological measures
reflecting left- and right-hemispheric and frontal-, parietal- and temporal-lobe function in 108
patients with schizophrenia and 63 matched controls. The neuropsychological battery included
tests of verbal fluency, Stroop interference, trail-making, block-design, Mooney faces recognition,
picture-completion, immediate and delayed visual and verbal recall. Paranoid and nonparanoid
subgroups were based on ratings from the Positive and Negative Syndrome Scale (PANSS). Groups
with high and low ratings of ideas-of-reference and thought-disorder were formed from a median
split on the Scale for Assessment of Positive Symptoms (SAPS).
Results: Verbal-fluency and Stroop-interference (left frontal and fronto-cingulate function) were
negatively associated with noradrenergic turnover in nonparanoid and thought-disordered
patients. High dopamine turnover related to speeded trail-making ( f r o n t a l  m o d u l a t i o n  o f  s e t
switching) in those with many ideas-of-reference. In contrast, low dopamine turnover predicted
poor recall in nonparanoid patients and those with little thought disorder. Serotonin metabolism
did not independently contribute to the prediction any measure of cognitive performance. But, with
regard to the relative activity between monoaminergic systems, increased HVA/5-HIAA ratios
predicted visual-reproduction and Mooney's face-recognition performance (right-hemisphere
functions) in highly symptomatic patients. Decreased HVA/MHPG predicted non-verbal recall.
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Conclusion: Clinical state and function are differentially sensitive to overall levels of monoamine
activity. In particular, right-lateralised cerebral function was sensitive to the relative activities of the
monoamines. Increased noradrenergic activity was associated with enhanced frontal but impaired
temporal lobe function in nonparanoid syndromes. Low dopaminergic activity predicted poor
attentional set control in those with ideas-of-reference, but poor recall in nonparanoid patients.
These data, especially the HVA/5-HIAA ratios, provide a basis for planning the nature of
antipsychotic treatment aimed at patient specific symptom dimensions and cognitive abilities.
Background
The idea that there may be a "group of schizophrenias"
among the psychotically ill is largely attributable to
Bleuler [1]. Yet, only in the last decade or so have studies
of the biological concomitants of schizophrenia explicitly
studied the 3–4 symptom dimensions making up the syn-
drome and taken account of their variation across patient
samples or within individuals over time. Carpenter et al.
noted that "Studies comparing a schizophrenia group
with a comparison group often show differences without
clarifying whether the difference relates only to a sub-
group of the subjects" [2]. The reverse also occurs. Many
studies report there is no difference between subject
groups without considering the potentially opposing
influences in the constituent subgroups (e.g. paranoid vs.
nonparanoid schizophrenia, [3]).
Few clinicians would expect measures of attentive abilities
in thought-disorganised patients to resemble those from
patients with nonparanoid negative symptoms, yet few
report on the biological variations that might underlie,
contribute to or modulate these differences. Here we
report on some indicators of such modulation (monoam-
ine transmitters) and the association of their activity with
measures of cognitive abilities in subgroups of
schizophrenia.
Such contrasts are illustrated in reviews by Amin et
al.[4,5]. Negative relations of the dopamine (DA) metab-
olite homovanillic acid (HVA) with numerous negative
symptoms and positive relationships with productive
symptoms have been reported frequently. Yet for summed
ratings of negative symptoms [6] no correlations with
plasma levels of HVA have been reported [7-9]. Just occa-
sionally, when a general diagnosis of schizophrenia has
been used, some biochemical associations with groups of
symptoms have been described (e.g. HVA correlated posi-
tively with anhedonia-asociality ratings [9], or negatively
with depression and hostility [10]).
Peripheral measures of monoamine metabolism may be
weak indicators of activity affecting the central systems:
but the changes that are registered are strong enough to be
relevant to the study of behaviour [12]. In particular, the
ratio of DA to serotonin (5-HT) metabolites (HVA/5-
HIAA: [5-hydroxyindole-acetic acid]) characterises some
patient groups. Low ratios are evident in thought-disor-
dered patients but high ratios in those with prominent
ideas-of-reference [11]. The amelioration of (usually) pos-
itive symptoms parallels changes in plasma HVA [13,14]
and these changes can be reflected in both plasma and cer-
ebrospinal fluid (CSF) samples [15-17]. For CSF, similar
correlations for the HVA/5-HIAA ratio with both symp-
toms and cognitive performance have been reported
[18,19]. Low CSF HVA/5-HIAA ratios were associated
with a persistent impairment and a poor outcome [20],
and increased ratios with a good response to treatment
[21]. As would be predicted from these CSF results,
plasma HVA/5-HIAA ratios rose in responders to treat-
ment with antipsychotic drugs [22] and approached nor-
mal levels after atypical vs. typical neuroleptic medication
[11]. Thus, as extensively argued before [4,5], plasma/
serum measures of monoamine metabolism and espe-
cially the ratio between their metabolites serve as a useful
proxy for widespread and general changes associated with
illness and medication.
There are several findings from studies of cognitive per-
formance that parallel the symptom-transmitter relation-
ships. Catecholamine metabolism affects early automatic
information processing in schizophrenia. Thus, DA
metabolism modulates the duration of the masking influ-
ence in backward-masking tasks [23], and sensory gating
of the startle response and event-related potentials
[24,25]. The improvement of gating was associated with
reductions of DA turnover (HVA/DA, [26,27]) and the
noradrenaline (NA) metabolite (MHPG, [28]). Subse-
quent controlled information processing can also be
influenced by each of the monoamines. Low levels of CSF
HVA (but not other metabolites) correlate with poor exec-
utive functions, such as card-sorting and visuo-spatial
recall [29]. Csernansky et al. [30] reported that CSF levels
of HVA correlated with those of 5-HIAA, but only the lat-
ter related to performance on WAIS tests reflecting atten-
tion-related abilities (digit-span, digit-symbol, picture
arrangement). With serum measures increased 5-HT turn-
over predicted not only the better gating of evoked poten-
tials, but improved Tower-of-London executive function,
especially for patients with symptoms of disorganisation
[26].Behavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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In this study the cognitive tasks were chosen to reflect
attentional and memory functions of the frontal and tem-
poral lobes frequently impaired in schizophrenia [31]. We
have reported on the neuropsychological performance
and on the characterisation of subgroups in terms of
monoamine metabolism: [11,32,33]. These are summa-
rised in the appropriate sections. Here we look at the asso-
ciations of monoamine activity with neuropsychological
abilities, and whether such associations relate to major
symptom dimensions (e.g. paranoid, thought-disorder
and ideas-of-reference). The aim is to improve under-
standing of the bases modulating cognition and the
expression of symptoms in patients with schizophrenia
and with such a profile to improve the monitoring and
titration of therapeutic measures for patients with differ-
ing symptom dimensions.
Based on the results reviewed above, we hypothesise 1)
that some features apparently characteristic of the whole
patient group (e.g. catecholamine activity) would be
largely attributable to a given sub-group (e.g. paranoid vs.
nonparanoid), with consequences for these patients' neu-
ropsychological abilities and antipsychotic drug
responses. More specifically, we suggest 2) that ratios of
DA to 5-HT activity (e.g. HVA/5-HIAA) would predict cog-
nitive impairments in disorganised patients, and that 3)
ideas-of-reference, (rarely the target of investigation but
with some similarities to productive symptoms) would be
associated with catecholamine activity. It is important to
bear in mind that the results reflect interactions of the type
of illness and treatment and do not reflect exclusively the
one or the other. Thus we discuss the results (i.e. the rela-
tionship of monoamine activity to task performance in
subgroups of patients) separately from three perspectives,
Table 1: Demographic and clinical data (means ± standard deviation) for 101 patients and 63 controls providing biochemical data on 
the left and neuropsychological performance scores on the right.
Demographic & Clinical Data Neuropsychological Tasks & Performance
Schizophrenics Controls Task Schizophrenics Controls
Age (years) 33.6 (11.0) 32.8 (11.0) Verbal fluency 28.6 (10.8) 35.0 (9.3)
Gender (m/f) 68 / 40 34 / 29 Mooney faces (hits) 9.8 (5.7) 8.6 (4.3)
Socio-economic group1 4.5 (1.9) 4.9 (1.6) Picture completion 11.8 (2.5) 14.3 (2.5)
Education (years) 13.3 (3.8) 13.7 (3.3) Block design 24.1 (9.5) 31.4 (7.7)
IQ (short APM) 6.9 (2.9) 9.9 (1.9) Vis Reprod (VR) 31.1 (5.0) 38.0 (3.5)
Handedness (Edinburgh) 17.5 (8.5) 18.9 (5.3) VR + delay 24.1 (9.1) 34.8 (6.0)
Onset-Age (years) 23.6 (8.4) Prose Reprod (PR) 17.7 (6.9) 29.8 (6.7)
First admission (years) 25.1 (9.6) PR + delay 13.1 (6.8) 26.3 (6.3)
Duration of illness (years) 9.5 (8.0) Trails B-A (sec) 79 (56) 35 (20)
Episode duration (days) 44.0 (40.3) Stroop Interfere (sec) 112 (38) 80 (20)
Diagnosis-
paranoid 70
disorganised 24
catatonic/residual 7
Symptoms,
PANSS positive 16.3 (6.0)
negative 18.6 (8.1)
general 36.8 (9.3)
SAPS ideas/reference 3.2 (3.8)
thought disorder 8.4 (6.5)
Extrapyramidal symptoms 5.8 (5.6)
AIMS 8.4 (2.9)
Antipsychotic drug dose
(CPZ: n = 99)2 665 (328)
typical + risperidone 572 (n = 49, 63% male, incl. 53% of paranoid, 29% of nonparanoid groups)
clozapine/olanzapine/sertindole 718 (n = 43, 67% male, incl. 33% of paranoid, 58% of nonparanoid groups)
Both 678 (n = 15, 47% male, incl. 14% of paranoid, 13% of nonparanoid groups)
Biperidene(mg/day: n = 15) 4.2 (1.8)
1. Scale 1–7, [84]: AIMS, Abnormal involuntary movement scale (n = 68/108 and 41/72); APM, Advanced progressive matrices; 2. CPZ, 
chlorpromazine equivalents, excluding 2 patients without medication; Biperidene is an anticholinergic drug (n = 15/108 and 9/72); PANSS, Positive 
and negative syndrome scale; SAPS, scale for assessment of positive symptoms; all neuropsychological tasks showed a significant group difference (p 
< 0.01) on point scores (low for patients) or latency (high for patients) except the Mooney faces test.Behavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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– profiles for symptom dimensions, for neuropsychologi-
cal function and for monoaminergic activity, in turn.
Results
Clinical Groups
Patients had been ill on average for 9.5y after onset of the
disorder at 23.6y and a first admission at 25.2y. The
groups did not differ in age, socio-economic status of the
parents or years in education. But the patients did show a
lower non-verbal IQ (F1,161 = 49.4, P < 0.0001: table 1).
Group and Sub-Group Biochemical Measures
For the patient group as a whole, turnover for 5-HT was
higher, for NA lower, and for DA there was no difference
compared to controls. The HVA/5-HIAA ratio was lower
in patients but along with catecholamine metabolites, lev-
els increased and normalised more on atypical than typi-
cal antipsychotic drug treatment (Fig. 1). There was a
trend for the HVA/MHPG ratio to be lower in the patient
group (Fig. 2 left).
Thought-disordered (disorganised) patients were charac-
terised by low levels of HVA, HVA/5-HIAA and HVA/
MHPG ratios, whereas high DA and 5-HT turnover and a
high HVA/5-HIAA ratio were features of those with ideas-
of-reference (IoR: Fig. 2 right). Nonparanoid patients
showed a much higher NA turnover than the paranoid
group. This was reflected in a trend for an increased DA
(Top) Serum monoamine and metabolite levels in controls (CON) and in patients treated with typical (TYP), atypical (ATYP)  or both types of antipsychotic drug Figure 1
(Top) Serum monoamine and metabolite levels in controls (CON) and in patients treated with typical (TYP), atypical (ATYP) 
or both types of antipsychotic drug. Atypical > Typical, * P < 0.1; ** P < 0.08; *** P < 0.04; # P < 0.006 (covaried for age, IQ and 
CPZ). (Bottom) Turnover rates for 3 monoamines, and the ratio of dopamine (DA) to noradrenaline (NA) and serotonin (5-
HT) metabolism (HVA/MHPG, HVA/5-HIAA), respectively. Controls (vs. whole patient group) showed less 5-HT TR (P < 0.05) 
and more HVA vs. 5-HIAA and MHPG (both ## P < 0.002).Behavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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turnover, where the HVA may have partly derived from
NA metabolism. The increased NA turnover parallels
plasma MHPG levels in patients with negative symptoms
and the deficit-syndrome [55]. The non-paranoid group
also had a larger HVA/5-HIAA ratio (Fig. 2 centre). We
reported previously that increased DA D2 occupancy was
predicted by decreases of DA metabolism and of HVA/5-
HIAA ratios, especially in paranoid patients. DA D2 occu-
pancy and catecholamine metabolism were unrelated in
nonparanoid patients [32].
Neuropsychology: Noradrenergic Activity
Patients were impaired in the performance of all tests
except the Mooney-faces-closure test [[33]: table 1]. Low
NA turnover, attributable to low levels of the metabolite
MHPG, was characteristic of the patient group as a whole
(Fig. 1), but was a significant feature for the paranoid vs.
the nonparanoid subgroup ([11] Fig. 2 centre).
A regression analysis showed significant effects of NA
turnover on Stroop-interference, and verbal fluency, with
opposite effects evident for controls and patients. For con-
trols (n, 60) increases of Stroop-interference were associ-
ated with increases of NA turnover (F1,58 = 7.4, P = 0.009:
r  = +0.34, R2 = 11.3%: Fig. 3, left). The inverse effect,
(increasing interference was associated with decreasing
NA turnover), was evident for the patients (n, 95: partial
correlation r = -.26, P < 0.01, Fig. 3 middle). However,
increased verbal fluency also remained in the last step of
this regression, and was clearly associated with decreases
of NA turnover (F2,92 = 5.5, P = 0.005; r = -0.29, P = 0.004,
Fig. 3 right). Together this explained 10.7% of the vari-
ance (R2). In other words, stimulation of the low levels of
NA TR in patients would be expected to improve (reduce)
interference in the incongruent Stroop condition but to
impair (reduce) verbal fluency.
There were no significant regression models predicting
relationships for NA turnover with neuropsychological
performance in paranoid patients (n 67) or the sub-
groups with marked IoR (n 39) and with little thought dis-
order (n 43).
Metabolite/monoamine turnover ratios for the whole subject group (bar diagram, left) and for patient sub-groups (tabular,  right: PN, paranoid; NP, nonparanoid; ThD, thought disorder [+/-, high/low]; IoR, ideas of reference [+/-, high/low]) Figure 2
Metabolite/monoamine turnover ratios for the whole subject group (bar diagram, left) and for patient sub-groups (tabular, 
right: PN, paranoid; NP, nonparanoid; ThD, thought disorder [+/-, high/low]; IoR, ideas of reference [+/-, high/low]). #P < 0.08, 
*P < 0.05, ** P < 0.01. 1 = levels of metabolite. Units: inter-amine ratios ×10; 5-HT TR ×103; DA and NA TR ×10.Behavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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However, the non-paranoid (n 28), thought-disordered
subgroups (n 51), and patients with few IoR (n 55)
showed very similar negative associations for NA activity
with verbal fluency. Thus, it was the nonparanoid,
thought disordered patients who were responsible for the
same effect seen with the patient group as a whole (Table
2 left). Nonparanoid patients with few IoR also showed
improving immediate verbal recall as delayed verbal recall
deteriorated with decreasing NA activity (Table 2 middle).
Like the patient group as a whole, thought-disordered
patients with few IoR showed increasing Stroop interfer-
ence with decreasing NA turnover. Their right hemisphere
functions such as set shifting latency (trails) and nonver-
bal recall were positively related to NA activity (Table 2).
As patients were showing lower than normal NA activity,
this means that decreases of NA turnover were associated
with poorer delayed recall. Short-term information
processing appeared to be enhanced by low NA activity
Partial correlations (left) for increased noradrenaline turnover (NA TR: Ln MHPG/NA) with increased Stroop-test interfer- ence scores in healthy controls (r = +0.34, P = 0.009), and (middle) for decreased NA TR with increased Stroop interference  scores in patients with schizophrenia (r = -0.26, P = 0.01) Figure 3
Partial correlations (left) for increased noradrenaline turnover (NA TR: Ln MHPG/NA) with increased Stroop-test interfer-
ence scores in healthy controls (r = +0.34, P = 0.009), and (middle) for decreased NA TR with increased Stroop interference 
scores in patients with schizophrenia (r = -0.26, P = 0.01). But, (right) decreases of NA TR are associated with better verbal 
fluency in patients with schizophrenia (r = -0.29, P = 0.004).
Table 2: Partial correlations for performance on 4 neuropsychological tasks reflecting left hemisphere (and cingulate) and two 
reflecting right hemisphere function with NA turnover in 3 patient sub-groups with few paranoid symptoms
Left hemisphere function Right hemisphere function
Verbal Stroop Immediate Delayed Trails B – A Delayed
Fluency Interference Verbal Recall Attention Set Visual Reproduction
p rprprprprpr p R 2
NP n 28
F(3,24) = 8.5, 0.0005 -0.60 0.001 -- -- -0.50 0.01 +0.60 0.001 -- -- -- -- 51.4%
High-ThD n 51
F(3,47) = 5.1, 0.004 -0.44 0.002 -0.34 0.017 -- -- -- -- -- -- +0.29 0.04 24.6%
Low-IoR n 55
F(5,49) = 4.7, 0.0014 -0.39 0.015 -0.33 0.005 -0.35 0.013 +0.42 0.002 +0.34 0.015 -- -- 32.3%
PN = paranoid, NP = Nonparanoid, High-ThD = above median summed thought disorder ratings, Low-IoR = below median of summed ideas-of-
reference ratingsBehavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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(e.g. verbal productivity and immediate verbal recall in
nonparanoid and thought disordered patients), but
Stroop and Trails indicators of set-shifting were associated
in opposite ways by changes of NA activity in patients
with few IoR.
Neuropsychology: Dopaminergic Activity
The patients as a whole did not differ significantly from
the healthy subjects on measures of DA turnover (Fig. 1:
[11]). But a trend for less DA activity in patients became
significant for the paranoid group (vs. nonparanoid). In
contrast, patients with marked IoR showed a higher DA
turnover than the other subgroups (Fig. 2).
For healthy controls (n 50) only the performance on the
picture completion task predicted DA turnover. Better per-
formance was associated with less DA activity (F1,48 = 6.8,
P = 0.012, r = -0.35, R2 = 12.4%: Fig. 4 left). For the patient
group as a whole (n 84) the dominant relationship for DA
turnover was with the immediate recall of stories. The effect
was the opposite of that described for NA turnover where
immediate  recall improved with decreasing NA activity
(above). Here, poor immediate recall was associated with
low, decreasing DA activity (F1,82 = 7.4, P = 0.008, r =
+0.29, R2 = 8.2%: Fig. 4 middle).
A further relationship of low DA turnover with poor ver-
bal recall was characteristic of those patients expressing
little thought-disorder and few IoR (Table 2). The one
striking relationship for increased DA turnover was in the
IoR subgroup. They tended to show high levels of DA
activity. Here increased DA activity was associated with
increased set-switching as indicated by decreased Trails B-
A differences (Fig. 4, right).
Neuropsychology: Ratio of Catecholamine Metabolites 
(Activity)
In controls, relative catecholamine activity (HVA/MHPG)
was unrelated to task performance. For the patients as a
whole (n 85) the opposing nature of the associations of
cognitive measures with DA and NA activity noted above
was reflected in a trend (F7,77 = 1.8, P = 0.09, R2 = 14.1%).
This showed opposite influences on the right hemisphere
functions of immediate and delayed visual reproduction
(r = +0.23, P = 0.04, r = -0.25, P = .03) and block-design
(r = + 0.22, P = 0.05).
Interestingly these right hemisphere functions reflected
the contributions of activity in the high IoR but nonpara-
noid subgroups (Table 3, right). In addition, in the high
IoR group negative relationships emerged for the left
Partial correlations (left) show that reduced dopamine turnover (DA TR: Ln HVA/DA) is associated with enhanced picture  completion scores in healthy subjects (r = -0.35, P = 0.01). Increasing DA TR (middle) is associated with improved verbal recall  in patients with schizophrenia (r = +0.29, P = 0.008) Figure 4
Partial correlations (left) show that reduced dopamine turnover (DA TR: Ln HVA/DA) is associated with enhanced picture 
completion scores in healthy subjects (r = -0.35, P = 0.01). Increasing DA TR (middle) is associated with improved verbal recall 
in patients with schizophrenia (r = +0.29, P = 0.008). For patients with high ratings for ideas-of reference (IoR: right) increased 
DA activity was associated with promoting the speed of switching between sets on the trail-making test (r = +0.34, P = 0.015).Behavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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hemisphere functions of verbal fluency and cingulate
mediation of Stroop interference (Table 3, left). As the DA
activity was relatively high in the high-IoR group,
increases of the ratio HVA/MHPG may be considered as
related to diminishing fluency, yet improved reduction of
interference.
Neuropsychology: Serotonergic Activity
The patient group showed a slight but significantly higher
level of 5-HT activity than the control group ([11] Fig. 2).
But among the subgroups only those expressing many IoR
showed more 5-HT activity than patients with few IoR.
Neither the patient nor the control group, neither the
paranoid nor the nonparanoid subgroup showed a model
where a significant part of the 5-HT turnover was
explained by neuropsychological task performance.
The only patients for whom 5-HT played a significant role
in task performance were those who expressed little
thought-disorder. This is of interest, firstly as 5-HT
metabolism has been reported to play a role in the task
performance of disorganised patients elsewhere (see dis-
cussion), and secondly because the task was also influ-
enced by catecholamine metabolism. For patients without
much thought disorder immediate verbal recall related
positively to 5-HT activity (Table 4). There was no signifi-
cant regression model for patients showing much thought
disorder nor for those with a rather high 5-HT turnover
(the high IoR subgroup).
Neuropsychology: Ratio of DA to 5-HT Metabolites 
(Activity)
Was the relative activity of DA to 5-HT (HVA/5-HIAA)
associated with any type of cognitive performance? In the
controls (n 51), with a higher ratio than in the patients
([11] Fig. 1), HVA/5-HIAA was associated negatively with
delayed visual reproduction (F1,49 = 10.2, P = 0.002, r = -
0.41, R2 = 17.2%). Picture-completion, a measure of right
hemisphere function, was also negatively related to DA
activity, but there was no direct influence of 5-HT activity.
The implication is that normal right hemisphere recall
mechanisms are driven by DA activity and mildly modu-
lated by 5-HT activity.
In the whole patient group, where low HVA/5-HIAA ratios
tended to normalise on atypical (vs. typical) antipsychotic
Table 3: Partial correlations for performance on 4 neuropsychological tasks reflecting left hemisphere (and cingulate) function and 4 
tasks reflecting right hemisphere function with DA turnover (A: DA TR) and the ratio of DA to NA activity (B: HVA/MHPG) in patient 
subgroups with few paranoid symptoms
Left hemisphere function Right hemisphere function
Verbal Stroop Immediate Delayed Block Trails B-A Mooney Delayed
Fluency Interference Verbal Recall Design Attention Set Faces Visual Reproduction
pr prpr pr pr pr p rprp R 2
a/ DA TR
NP n 28
F(1,26) = 5.6, 0.026 -- -- -- -- -- -- -- -- -- -- -- -- -0.42 0.026 -- -- 16.3%
Low-ThD n 41
F(1,39) = 8.7, 0.005 -- -- -- -- +0.43 0.005 -- -- -- -- -- -- -- -- -- -- 18.3%
High-ThD n 43 N.S. -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
Low-IoR n 48
F(1,46) = 3.9, 0.05 -- -- -- -- +0.28 0.05 -- -- -- -- -- -- -- -- -- -- 7.9%
High-IoR n 36
F(1,34) = 8.3, 0.007 -- -- -- -- -- -- -- -- -- -- -0.44 0.007 -- -- -- -- 19.6% -
b/HVA/MHPG
NP n 25
F(1,23) = 5.0, 0.036 -- -- -- -- -- -- -- -- +0.42 0.036 -- -- -- -- -- -- 17.8%
Low-ThD n 45
F(1,48) = 4.7, 0.037 -- -- -- -- -- -- +0.33 0.037 -- -- -- -- -- -- -- -- 10.9%
High-ThDn 45 N.S. -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
Low-IoR n 47
F(3,43) = 2.3, 0.095 +0.30 0.047 -- -- -- -- -- -- -- -- -- -- -- -- -- -- 13.6%
High-IoR n 38
F(4,33) = 4.7, 0.004 -0.35 -0.35 -0.50 0.002 -- -- -- -- +0.50 0.002 -- -- -- -- -0.36 0.03 36.3%
PN = paranoid, NP = Nonparanoid, Low-/High-ThD/IoR = below /above a median split of thought disorder/ideas-of reference ratings. NS = Model 
not significantBehavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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medication (Fig. 1), the relative activity of DA to 5-HT sys-
tems was related clearly to the performance on no less
than 4 tasks (F5,79 = 3.5, P = 0.006). The one is character-
istic of left hemisphere function (verbal fluency: r = +0.23,
P = 0.04), while the other 3 tasks reflect right hemisphere
function (Mooney-faces; r +0.26, p = 0.02: immediate vis-
ual reproduction; r  = +0.31, P  = 0.005: delayed visual
reproduction; r -0.24, P = 0.03).
Analyses of the sub-groups showed that marked positive
associations with the Mooney-faces task were contributed
by patients who were paranoid, with many IoR (Table 4,
bottom). Other right hemisphere functions where HVA/5-
HIAA was important (e.g. visual reproduction and picture
completion) were found in patients with many IoR but lit-
tle thought disorder (Table 4). Striking is the large degree
of variance explained for non-verbal memory processes,
Mooney faces recognition and trails' measures of set-shift-
ing in patients with marked IoR (whose HVA/5-HIAA
ratios were significantly above those with few IoR).
Discussion
This is the first comprehensive report of potential func-
tionally-related associations between neuropsychological
performance and plasma markers of the overall activity of
3 monoamines in normal subjects and those with schizo-
phrenia. Novel is that the regression analyses take account
of the heterogeneity of schizophrenia, whereby 3 major
dimensions of the clinical presentation of schizophrenia
were examined: paranoid-nonparanoid, disorganisation/
thought-disorder and ideas-of-reference. The tasks repre-
sented cognitive contributions of the frontal or temporal
lobes in the left or right hemispheres. We now draw
together profiles with respect to the variance explained
from the perspective of nosological, neuropsychological
and biochemical descriptors.
On the variance explained
First we consider the main results from the point of view
of the degree of variance explained in the regression anal-
yses. Considering the whole groups of patients and con-
trols, there was no example of neuropsychological
performance relating to the variance of 5-HT turnover.
Table 4: Partial correlations for performance on 4 neuropsychological tasks reflecting left hemisphere (and cingulate) function and 2 
tasks reflecting right hemisphere function with 5-HT turnover (A: 5-HT TR) and the ratio of DA to 5-HT activity (B: HVA/5-HIAA) in 
patient sub-groups
Left hemisphere function Right hemisphere function
Verbal Immediate Picture Mooney Trails B – A Immedate Delayed
Fluency Verbal Recall Completion Faces Attention Set Visual Reproduction
prpr p rp rprprprpR 2
a/ 5-HT TR
NP n 26 N.S. -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
PN n 70 N.S. -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
Low-ThD n 46
F(1,44) = 4.3 0.04 -- -- +0.30 0.04 -- -- -- -- -- -- -- -- -- -- 8.8%
High-ThD n 49 N.S. -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
Low-IoR n 55 N.S. -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
High-IoR n 40 N.S. -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
b/ HVA/5-HIAA
NP n 26 N.S. -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
PN n 59
F(1,57) = 4.1, 0.04 -- -- -- -- -- -- +0.26 0.04 -- -- -- -- -- -- 6.7%
Low-ThD n 41
F(5,35) = 3.5, 0.01 +0.36 0.028 -- -- -0.40 0.01 -- -- -- -- +0.45 0.005 -0.29 0.07 33.3%
High-ThD n 43
F(1,41) = 4.7, 0.035 -- -- -- -- -- -- +0.32 0.035 -- -- -- -- -- -- 10.4%
Low-IoR n 53 N.S. -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
High-IoR n 31
F'F(4,26) = 5.7, 0.002 -- -- -- -- -- -- +0.51 0.005 -0.50 0.006 +0.53 0.004 -0.48 0.009 46.7%
PN = paranoid, NP = Nonparanoid, Low-/High-ThD/IoR = below /above a median split of thought disorder/ideas-of reference ratings. NS = Model 
not significantBehavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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This may reflect an over-proportional contribution from
peripheral organs [56]. Theoretically, opposite effects in
mutually exclusive subgroups could also be responsible.
In practice it should be noted that 5-HT metabolism did
have a modulatory effect in some subgroup analyses. In
contrast, there were examples in both healthy and patient
groups of cognitive performance having a predictive rela-
tionship for 8–12% of the variance of NA and DA turno-
ver. A correlation with frontal lobe function was evident
with NA activity (Stroop and verbal fluency), while DA
activity related to posterior temporo-parietal function
(picture completion and immediate verbal recall).
With respect to the subgroups of schizophrenia, the great-
est amount of variance was explained in analyses showing
similar contributions of the performance on 3–4 tasks to
the monoaminergic ratio considered. This is not
surprising as the widespread innervation by monoaminer-
gic systems would be expected to contribute to functions
sensitive to several tasks. The most striking example was
with non-paranoid NA turnover as the independent vari-
able. Here 3 left-hemisphere functions contributed over
50% of the variance (verbal fluency, immediate and
delayed verbal recall). Three more large contributions to
the variance related to the relative activity of the monoam-
ines. Two concerned the patients with marked ideas-of-
reference (IoR). For HVA/5-HIAA, right-hemisphere func-
tion predominated (trails, Mooney-faces, immediate and
delayed visual recall: 47% of the variance). This may
implicate a more dominant contribution of DA activity in
view of the sparse associations for 5-HT turnover (see
below). HVA/MHPG also correlated with performance on
4 tasks (36% of the variance). The two right hemisphere
tasks may reflect the contribution of DA activity to more
posterior parietal and temporal lobe function (block-
design and visual delayed recall, see previous paragraph).
Tasks reflecting the left-hemisphere (verbal fluency) and
midline cingulate function (Stroop) may reflect the dom-
inant role of NA activity, prominent in nonparanoid sub-
jects (see above).
Profiles – nosological
In paranoid patients the single significant association con-
cerned HVA/5-HIAA and Mooney-faces performance. This
positive association contrasts with the negative relation-
ship with DA activity seen in nonparanoid subjects for
Mooney faces. The contrast points to the potential nega-
tive influence of increasing DA activity (levels were higher
in the nonparanoid group), and the positive influence of
increasing HVA/5-HIAA ratios with atypical antipsychotic
drugs (that benefited the paranoid patients in particular).
Further the paranoid/nonparanoid contrast illustrates
well a point made in the introduction: namely, the whole
patient group did not show impaired performance on the
Mooney faces task (Table 1) despite clearly opposing ten-
dencies in the constituent sub-groups. Otherwise nonpar-
anoid patients were characterised by a) the absence of a
relationship between cognitive function and 5-HT activ-
ity, where a previous report found low activity related to
slow discrimination learning [57], and b) a strong rela-
tionship with NA activity (nonparanoid> paranoid, Fig.
3), where increases related to improved delayed verbal
recall, but to less verbal productivity – that is usually poor
in this subgroup [58].
Like the nonparanoid group, patients with little thought-
disorder showed a relationship between frontal functions
and NA activity. But they also showed a relationship of the
performance on 5 tasks to an aspect of 5-HT activity (turn-
over or the ratio to DA activity). Indeed one might posit a
similar role for the relative strength of DA/5-HT activity in
immediate verbal and visual recall, picture completion
and even verbal fluency. In contrast those with high levels
of thought-disorder had a limited set of associations with
left frontal (NA) function and right parietal involvement
(HVA/5-HIAA). The relatively high levels of 5-HT activity
found in these thought-disordered patients tends to be
supported by drug-challenge, genetic and plasma meas-
ures [59-61].
For subjects with few or with marked IoR there was a
remarkable set of associations between cognition and
monoamine activity. For those with few IoR left hemi-
sphere (frontal and temporal lobe) cognitive function
related to NA metabolism. But in patients with strong IoR,
right hemisphere functions (trails, Mooney-faces, imme-
diate and delayed visual recall) were related to HVA/5-
HIAA. It is notable that some of the latter functions incur
parietal activity that was reported to be high in imaging
studies of patients with marked IoR [62].
Profiles – monoamines
NA activity correlated with neuropsychologic function in
patients with much thought disorder and those who were
nonparanoid with few IoR. Decreasing NA metabolism
was favourably related to improved verbal fluency, and
less Stroop interference. Further the decreases of NA
metabolism in nonparanoid patients with few IoR related
to better immediate verbal recall. These normalising
effects of decreasing NA activity in thought disordered
patients concur with reports on plasma levels of MHPG
[63], and results achieved on trials of NA antagonists
[64,65].
Increases of DA activity related positively to improved
immediate verbal recall in those without much thought
disorder or IoR. On the other hand increasing DA activity
was related to reduced Mooney-faces scores in nonpara-
noid patients and faster switching of set in the trails task.
This is consistent with decreases of switching performanceBehavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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registered after treatment with DA antagonists (e.g.
antisaccades, trails, Stroop; [66]). The relative degree of
DA to NA activity (i.e. HVA/MHPG) was important for left
and right hemisphere function (4 tasks) especially in
those with marked IoR (Table 2, bottom).
For 5-HT activity, the important issue for cognitive func-
tion was its activity relative to that of DA (HVA/5-HIAA).
This may reflect the opposing influences of DA and 5-HT
on the processes underlying efficient cognitive function
(e.g. working memory, [67]). The importance of the ratio
was evident in patients with productive symptoms (para-
noid), much thought-disorder and IoR. The direction of
the association could be negative or positive, but remark-
able is that the functions largely belong to the domain of
the right hemisphere (Table 4 bottom).
Profiles – Neuropsychology
Here we point out only the strongest relationships for the
10 neuropsychological tasks. For verbal fluency and
Stroop interference (signs of frontal and cingulate func-
tions) correlations were seen in highly symptomatic
patients. Verbal fluency was reduced with increasing NA
activity in the thought-disordered and those with negative
symptoms (nonparanoid). This seems to parallel the
sharp rise (then fall) of negative symptoms and plasma
NA levels in a study of the effects of ketamine-induced
psychosis [68]. However, they reported associations with
impaired verbal memory rather than fluency – although it
is difficult to be sure what the state of the NA response was
in each task. NA activity was also implicated in those with
many IoR where decreasing HVA/MHPG ratios were asso-
ciated with increased Stroop interference. For those with
high IoR, decreasing latencies on the trails B-A task, a fron-
tal sign of the ability to shift between set, related to
increasing DA turnover and HVA/5-HIAA ratios. In the
same patients worsening block-design and Mooney-faces
performance (signs of parietal function) related to
decreasing HVA/MHPG and HVA/5-HIAA, respectively.
Among the few studies of this patient subgroup, others
have noted an association between IoR symptoms and
performance on tests of self-monitoring abilities such as
these [69], and for ketamine-induced IoR with DA bind-
ing activity [70].
A remarkable feature across analyses is that the signs of
the correlations for immediate verbal or visual recall usu-
ally changed for the delayed recall version (Table 2 left,
Table 4 right). Nonetheless poorer immediate verbal
recall was associated with decreasing DA turnover in the
low thought-disorder group, while poorer delayed verbal
recall related to decreasing NA turnover in the nonpara-
noid patients. One could perhaps generalise this result:
poor recall abilities are associated with low catecholamine
activity, especially in patients not showing positive and
productive symptoms.
General: methods – advantages/disadvantages
Many previous reports have deliberated over the interpre-
tation of biochemical data collected remotely from the
source; CSF, blood (plasma) and urinary measures pro-
vide peripheral data remote from the CNS monoamine
pathways producing them. Nonetheless, all the products
of monoamine metabolism will spill over and be reflected
in peripheral catchments on the way to breakdown and
excretion. Major psychological or psychiatric states and
drug treatment are the most likely agents for changes of
transmitter activity from the norm. Schizophrenia and
antipsychotic drugs are here widely documented cases in
point, where changes of monoaminergic activity clearly
affect peripheral and central functions alike.
We argue that the obvious disadvantages of this study in
not being able to measure at source are partly counter-
acted by two innovations. The first is the more precise
description of the clinical state. We suggested in the intro-
duction that clinicians easily distinguish the confused
thought processes of disorganised patients from those
who hallucinate frequently. Further, the clearly separate
substrates responsible are not only reflected in different
neuropsychological performance and state but reflect dif-
ferent levels of monoaminergic activity. By separating
these factors it should be possible to find relationships
between cognition and monoamine activity in the direc-
tion of those reported here. We limited ourselves to
extreme states on the dimensions of paranoia, disorgani-
sation and ideas-of reference (6 groups). Others would do
well to study the relations for negative symptoms: (e.g. are
plasma HVA levels higher in deficit vs. nondeficit schizo-
phrenia [55] or vice versa due to symptom profile [71] or
typical antipsychotic treatment [72], or is the type of onset
critical (abrupt/gradual) where the age of onset was unre-
lated to plasma HVA levels [10]?).
The second innovation was the use of turnover measures
of metabolism and inter-amine activity ratios. This was
intended to resolve the following issue. Reliance on
amine measures may, in the case of (say) high levels,
reflect increased release resulting from increased meta-
bolic demand, and increased impulse flow [73]. But they
may also reflect production over the need, as often seen
when circumstances change or the ongoing state inhibits
an adaptive reduction of release. With these innovations
we proposed to find changes and relationships that have
otherwise been masked by the study of subgroups with
opposing tendencies within the population under investi-
gation. This may have been the case with reports of the
absence of associations found in relatively chronic adult
patients [74] and adolescents with a more recent onsetBehavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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[75]. A third important feature of this study helped add
precision to a close description of psychiatric state and the
general state of monoaminergic activity. This has been the
ability through recent neuroimaging and brain-damage
studies to relate the above changes of biochemical and
psychological state to the function of gross divisions of
the CNS in performing well-studied neuropsychological
tasks [76].
General: conflict and consistency in CSF monoamine 
findings
CSF levels of NA were reported to be unrelated to verbal
abilities, arithmetic or memory function [74,75,77]. CSF
MHPG levels were not associated with performance on
tasks testing memory and executive function [29]. Such
negative results are unexpected considering that high NA
(potentially reflecting a low turnover) and decreasing
MHPG levels in the CSF have been associated with
increasing psychopathology [77,78]. But, some appar-
ently conflicting findings [77] are consistent with our
results in one aspect. The psychopathology they described
related to positive symptoms: it was in such paranoid
patients that we found a lower NA turnover. Further the
absence of a relationship for NA levels with verbal abili-
ties and memory [77] is explicable by our finding that
decreasing NA activity related to improved verbal fluency
and recall. The subtle difference is that we found this rela-
tionship most evident in patients who suffered much
thought disorder or few IoR or paranoid symptoms –
those with higher NA turnover.
CSF levels of 5-HIAA have been related to performance on
tests of attention, working memory and executive func-
tion as measured by the digit-symbol, digit-span and pic-
ture arrangement tasks [19,30]. Both groups noted a
correlation between HVA and 5-HIAA levels, and the rela-
tionship of HVA/5-HIAA to both cognitive measures and
symptom ratings [19]. So it is not surprising and support-
ive of our methods that we also found that a clinical
improvement following atypical antipsychotic drug-treat-
ment was associated with increased HVA/5-HIAA ratios
[11], and that several cognitive functions (associated with
the right hemisphere) improved or worsened with
increases and decreases of the HVA/5-HIAA ratio, respec-
tively. Novel was the finding that this relationship was
marked for patients with many IoR and little thought dis-
order in the trails-measure of attention-shift and in visual
memory. In contrast, those with thought-disorder and
paranoia showed similar relationships but restricted to
the Mooney-faces-closure test (Table 4).
It was surprising to find relatively few relationships
between DA activity and task performance, considering
there was a broad range of high to low values among the
healthy subjects and suppressed levels among patients –
to which both the illness and medication would have con-
tributed. However, it may be noted that even with other
patient groups (e.g. HIV: [79]), where CSF HVA levels
were <50% of the non-affected controls, correlations were
restricted to response slowing on tests of executive atten-
tion and concentration and unrelated to memory per-
formance. For elderly subjects an inverse relationship
between plasma HVA and bradykinesia was reported [80],
which to a degree is consistent with studies of schizophre-
nia [29] and schizotypal disorder [17] where more neu-
ropsychological impairment was observed with
decreasing levels of CSF HVA. Our finding of a positive
relationship with HVA for immediate verbal recall in
patients without thought disorder and IoR (Table 2) fits
into this pattern, but contrasts with plasma HVA findings
in a sample of chronically ill patients [81]. But we agree
with a report from the same research group [19], that
where there was a lack of association with HVA alone, the
ratio HVA/5-HIAA explained performance better. (Note:
typical antipsychotic drugs impair performance on many
tests of memory [82], but some of the above results were
obtained with non-medicated subjects [17] and, in this
report with subjects on atypical antipsychotic
medication.)
The one intriguing exception to these reports on the
effects of decreases of HVA concerned patients showing
many IoR. These patients not only showed unusually high
levels of DA metabolism but also a correlation of shorter
set-shift latencies on the trails' test with increasing DA
turnover. This fits well with an early formulation of the
role of DA in switching between information processing
channels [83] and could form the basis of a working
hypothesis for future study of the bases of these patients'
illusions. Namely, that the increased DA activity permits
switching between multiple associations for a given sen-
sory input, permitting in the pathological case a grossly
inappropriate interpretation of incoming information.
In conclusion, the profiles of the associations of neu-
ropsychological performance with changes of activity of
dopamine, noradrenaline and serotonin (and their activi-
ties relative to each other), can assist with an understand-
ing of the modulation by monoaminergic pathways of
frontal and temporal lobe function. This pertains even
though the origin of the peripheral monoamine measures
cannot be attributed to any particular anatomical source.
Since this report concentrates on patients showing strong
or few symptoms on three major dimensions of psycho-
pathology, the profiles for these sub-groups of schizo-
phrenia should help to inform goal-directed interventions
in the treatment of patients with these particular features.Behavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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Methods
Subjects
Using DSM-IV criteria [34] 108 patients from the Univer-
sity Psychiatry Clinics were diagnosed with schizophrenia
by the senior ward physician and subsequently by 2 senior
physicians associated with this research. Affective,
schizoaffective and schizophreniform psychoses were
excluded. The undifferentiated subtype was regarded as a
residual category that contrasts with the paranoid, disor-
ganised and catatonic subtypes. Patients were screened to
exclude other major psychiatric or somatic illness, alcohol
abuse in the last 5 years and substance abuse other than
nicotine at the time of testing. A group of 63 healthy con-
trols, recruited by advertisement and paid for their partic-
ipation, was closely matched for age, education, socio-
economic family status and handedness. Exclusion crite-
ria for controls were the same as for patients, and based on
a semi-structured interview: they reported no family his-
tory of psychosis, nor that they had ever consulted with a
psychiatrist or psychologist. Following approval from the
Hospital Ethics Committee, in accord with the Declara-
tion of Helsinki informed signed consent was obtained
from each patient and the responsible care-giver, and
from each healthy participant. Clinical and demographic
data are given in table 1.
The study took place in the post-acute phase, on average 6
weeks after the patient's admission (range 4–8 weeks) and
following stabilisation of treatment. Of 101 patients pro-
viding biochemical data 99 were treated with antipsy-
chotic drugs according to their clinical requirements. Drug
doses were converted to chlorpromazine equivalents
(CPZ: [[35-38], correspondence with the suppliers of
olanzapine and sertindole]). Patients receiving conven-
tional, atypical or both categories of antipsychotic drug
were considered separately and together [[11]: table 1].
Symptoms were rated with the Positive and Negative Syn-
drome Scale (PANSS: [39], along with Schneiderian ideas-
of-reference (ego-disturbance) and thought-disorder
items from the Scale for Assessment of Positive Symptoms
(SAPS: [6]) that are under-represented in the PANSS. The
subtypes of schizophrenia was based on a factor analysis
of the symptom ratings. This resulted in 4 dimensions
(varimax rotation, eigen values >1, excluding those con-
tributing <5% to the variance: [3]): (1) disorganised
(especially thought/concept disorder), (2) nonparanoid
(largely negative symptoms), (3) ideas-of-reference and
(4) paranoid (positive symptoms). Four categorical
groupings were made on the basis of this factor analysis.
Thought disorder (ThD) and ideas-of-reference (IoR) rat-
ings were split at the median to provide groups with high
vs. low levels of the respective symptom clusters.
Paralleling the paranoid/nonparanoid (PN/NP) diagnos-
tic split, two mutually exclusive groups with PN and NP
symptoms were formed. This procedure resulted in a com-
parison of 6 subgroups of patients with schizophrenia.
Neuropsychology
Ten tasks were administered. The verbal-fluency test [40]
required the generation of as many words as possible
starting with the letter F, A or S (1 minute each). In the
trail-making test subjects were asked to join up in
sequence first a series of numbers (form-A), then an alter-
nating series of letters and numbers (form-B, e.g. 1-A-2-B-
3; the score used was the form-B-minus-A latency; [41]).
These tests reflect functions in the left and right frontal
lobes, respectively [33]. The Stroop test interference score
was the increased latency to name the print colour of a
word that named a different colour compared to the laten-
cies to name colours and words naming colours. Perform-
ance activates the frontal and cingulate cortices [42,43].
The block-design and Mooney faces closure tests reflect
broadly parietal function. Block-design required that a
given square form was reconstructed out of 4 or 9 pieces
[44]. The modified Mooney faces closure test asked for the
classification of the age of degraded images of faces
[45,46]. In the picture-completion test (a reflection of
temporo-parietal function) the subject identified the
missing feature on a picture of an everyday scene [44]. Vis-
ual reproduction and logical memories under conditions
of immediate- and delayed-recall [47] involved a presen-
tation of a series of visual patterns or two short stories for
recall, and reflect right- and left-sided temporal lobe func-
tion in visuo-spatial and verbal memory, respectively. In
addition the short 12-item form of the Advanced Progres-
sive Matrices (APM) was used as a measure of IQ, where
scores <6 are below and scores of 12 are above average
[[48]: table 1].
Serum assessments and assays for monoamines and their 
metabolites
A 30 ml blood sample was taken at 08.00 (± 30 min) after
10 h of fast and rest before smoking, medication, exercise
and breakfast. The sample was centrifuged for 10 min at
2000 g and stored at -70°C until analysis. All samples
were analysed blind to their origin by reversed phase high
performance liquid chromatography with a glassy carbon
electrochemical detector using internal standards. Sepa-
rate isocratic determinations were run for a) DA and NA,
b) 5-HT with organic-sodium dihydrophosphate mobile
phases [after [49]], c) HVA, 5-HIAA, [50] and d) MHPG
with organic sodium-acetate mobile phases [51]. Intra-
and inter-assay coefficients of variation were, DA 11.6/
8.9%, NA 11.6/9.1%, 5-HT 2.3/9.2%, HVA 7.1/19.8%, 5-
HIAA 6.0/7.3% and MHPG 6.9/18.1%, respectively.
Recovery ranged from ca. 74–80% with the following sen-
sitivities (ng/mL) for DA 0.5, NA 0.01, 5-HT 1.0, HVA and
5-HIAA 1.25, and MHPG 1.0.Behavioral and Brain Functions 2005, 1:14 http://www.behavioralandbrainfunctions.com/content/1/1/14
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Serotonergic measures allowed for the taking of compara-
ble metabolic measures between monoamines. Circulat-
ing levels can be expressed in terms of platelet numbers,
their protein content, or per unit volume of blood, serum
or platelet-rich plasma. The first two methods may be con-
taminated by non-platelet derivatives and their proteins,
while the latter 3 measures can vary with efflux from the
platelets. Nonetheless, a high correlation between platelet
and circulating levels with excellent intra-individual repli-
cability at 3 months has been repeatedly reported for
healthy subjects [52,53]. Our values match those of Jernej
[53] and 5 studies discussed (98–312 ng/ml), and are a bit
lower than in 3 reports on platelet-rich plasma and serum
(269–271 ng/ml). Turnover rates were similar to plasma
values [54]. The scarcity of outliers (± 2 SD) was similar
between the monoamines, does not point to irregular
platelet-release and emphasises the lack of variability.
Data treatment
The biochemical data from 5 subjects were above a cut-off
criterion for outliers of the mean ± 2 SD and removed
from the analysis. For technical reasons some data were
missing from individual measures and covariates for 15
subjects. This resulted in full sets of data across all meas-
ures in 73 patients and 37, less a further 10 patients for the
metabolite ratios. Their demographic and clinical charac-
teristics did not differ from the original sample [32]. The
number of subjects used in each analysis is cited below in
parentheses. Normal distributions of the biochemical
data were obtained after natural logarithmic
transformations.
Separate multivariate analyses of covariance were used to
compare task performance or biochemical measure
between subject groups. Age and IQ were related to some
biochemical measures, and therefore used as covariates.
Other demographic variables (e.g. education, status) were
not used: they were matched between groups, their vari-
ance was not large and their communal contribution over-
lapped with age and IQ. Biochemical data were analysed
in two stages. The first considered the 3 monoamines and
their 3 metabolites [11]. The second, forming the basis for
the present report, concerned the 3 turnover ratios and
two inter-amine metabolite ratios (e.g. HVA/5-HIAA,
HVA/MHPG). The differential effect of conventional and
atypical medication was controlled for the effect of dose
with the use of chlorpromazine equivalents (CPZ) as cov-
ariate. The locus of effect was sought by t-tests (patient
data) and one-way analyses of variance (neuropsychology
and biochemistry). The relationships of clinical sub-
groups to biochemical measures, and neuropsychological
performance were reported in Oades et al. [11,32,33] and
are described here only in summary form.
The emphasis in the present report lies with an explana-
tion of the contribution to test performance by the groups
and subgroups of patients and the controls made by meas-
ures of plasma monoamine activity with the use of stand-
ard, linear regression models. First task performances (n
10) were entered into equations for turnover measures in
the patient and control groups. Following significant
standard regression models at α = 0.01, the relationships
for the 6 sub-groups of patients for explanation by 5 meas-
ures of biochemical ratios were explored with backward,
step-wise, linear regression models. We emphasise an α-
correction to 0.001% for significance. However, in view of
the exploratory nature of the study and the inherent
uncertainties associated with the models, we describe
trends up to levels of <0.05%.
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